PHIT-Brain Study Protocol: Adaptation and Evaluation of a Multifaceted Brain Health Intervention for Patients with Parkinson’s Disease and Mild Cognitive Impairment (PD-MCI)
Objective: The aim is to adapt a brain health program for the PD population, the Parkinson’s Health Initiative for Thinking and the Brain (PHIT Brain),…Caregiver Burden after DBS at GPI or STN for Parkinson’s Disease
Objective: Examine the effects of GPi or STN DBS on caregiver burden for Parkinson's Disease Background: Deep Brain Stimulation (DBS) is a common treatment used…Anti-Diabetic Medications to Fight Parkinson’s Disease and Lewy Body Dementia
Objective: To evaluate the tolerability and clinical effects of newer antidiabetic drugs in individuals with Parkinson's disease (PD) and Lewy body dementia (LBD). Background: Parkinson’s…Reduced Falls With ND0612: Supportive Analyses From the BouNDless Phase 3 Study
Objective: Explore potential reasons for the lower rates of falls with ND0612 vs immediate-release levodopa/carbidopa (IR-LD/CD) therapy reported in the BouNDless study. Background: Falls are…The NICE-PD Trial: Cost-Effectiveness of Specialized Nursing Interventions for People with Parkinson’s Disease
Objective: We aimed to assess the cost-effectiveness of adding specialized nursing care to usual care compared with usual care alone in people with Parkinson’s disease…Effect of Allogeneic Bone-Marrow Derived Mesenchymal Stem Cell Therapy on Quality of Life in Patients with Parkinson’s Disease
Objective: To assess the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) infusions on the quality of life (QoL) of patients with…Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials
Objective: To characterize the lived experience of individuals at a prodromal stage of PD or with a recent clinical diagnosis. Background: There is no validated…CSM-101 is a Small Molecule Agonist of TRPML1 for Parkinson’s-Related Disorders
Objective: (i) To develop a brain-penetrant small molecule agonist for the lysosomal TRPML1 channel and, (ii) Perform preclinical studies supporting development in Parkinson’s-related disorders. Background:…Dietary Caffeic Acid Exhibits Neuroprotective and Neuromodulatory Effects in a Parkinsonian Rat Model by Mitigating Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis
Objective: This study investigated the neuroprotective and neuromodulatory effects of dietary caffeic acid (CA) in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonian rat model Background: Parkinson’s disease (PD)…Relationship Between Improvement in “On” Time, Nonmotor Symptoms, and Quality of Life in Adults Treated With Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease
Objective: To determine if adults with advanced Parkinson’s disease (aPD) treated with a 24‑hour/day continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) infusion who had ≥ 1‑hour improvement in…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.